I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers
Launched by NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) · Nov 3, 1999
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse. \[I-123\] Beta-CIT is a recently developed radioligand for SPECT imaging of dopamine and serotonin transporters. \[I-123\]Beta-CIT SPECT has been used at the SPECT-Lab of the Clinical Brain Disorders Branch in over fifty subjects without adverse events. Due to the trace concentrations used, a pharmacological effect of Beta-CIT is unlikely and has not been observed. The purpose of this study is to use Beta-CIT and SPECT to study the expression of dopamine an...
Gender
ALL
Eligibility criteria
- INCLUSION CRITERIA:
- • No Axis I or Axis II diagnoses.
- EXCLUSION CRITERIA FOR ALL SUBJECTS:
- • If the pregnancy test is positive or if the woman has reason to believe she might be pregnant, she will be excluded from this study.
- • Women who are breastfeeding will be excluded from this study to avoid unwarranted risk to their children.
- • Subjects with a prior reaction to iodine, iodine compounds, or shellfish will be excluded from this study.
- • Subjects with a history of thyroid disease or dysfunction will be excluded from this study.
- • Subjects with a history of recent substance abuse will be excluded from this study.
- • Subjects with metal objects in their bodies as specified in our MRI protocol (91-M-0124) will be excluded from this study.
- • If a structural abnormality of the brain is detected on MRI, subjects will be excluded from the study.
- EXCLUSION CRITERIA FOR NORMAL CONTROLS:
- • Subjects with an Axis I or Axis II disorder will be excluded.
- • Subjects with concomitant medical or neurological disorders which require ongoing medication, or which may affect the central nervous system will be excluded.
About National Institute Of Mental Health (Nimh)
The National Institute of Mental Health (NIMH) is a leading federal agency dedicated to advancing the understanding and treatment of mental health disorders through innovative research and clinical trials. As part of the National Institutes of Health (NIH), NIMH focuses on a broad spectrum of mental health issues, including mood disorders, anxiety disorders, schizophrenia, and developmental disorders. By fostering collaboration among researchers, clinicians, and the community, NIMH aims to translate scientific discoveries into effective interventions and improve mental health outcomes for individuals across the lifespan. Through its commitment to rigorous research methodologies and ethical standards, NIMH plays a pivotal role in shaping the future of mental health care and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials